Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junia Melo

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Clinical Hematology International|July 16, 2024
Scientific writing: how to get publishedJunia Melo, Mohamad Mohty
The Hematology Journal : the Official Journal of the European Haematology Association|June 11, 2004
Switching off oncogenic signals in chronic myeloid leukaemiaJunia Melo, David J Barnes
Blood|June 6, 2003
Monitoring CML after nonmyeloablative transplantations: how negative is negative?Jaspal Kaeda, Jane Apperley, Junia Melo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implicationsDevendra K Hiwase, Verity Saunders, Duncan Hewett, et al.
Haematologica|April 21, 2009
The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinibJamshid Sorouri Khorashad, Simon Wagner, Liat Greener, et al.
Blood|September 9, 2006
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disordersMarianna David, Nicholas C P Cross, Sonja Burgstaller, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Clinical Hematology International|July 16, 2024
Scientific writing: how to get publishedJunia Melo, Mohamad Mohty
The Hematology Journal : the Official Journal of the European Haematology Association|June 11, 2004
Switching off oncogenic signals in chronic myeloid leukaemiaJunia Melo, David J Barnes
Blood|June 6, 2003
Monitoring CML after nonmyeloablative transplantations: how negative is negative?Jaspal Kaeda, Jane Apperley, Junia Melo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implicationsDevendra K Hiwase, Verity Saunders, Duncan Hewett, et al.
Haematologica|April 21, 2009
The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinibJamshid Sorouri Khorashad, Simon Wagner, Liat Greener, et al.
Blood|September 9, 2006
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disordersMarianna David, Nicholas C P Cross, Sonja Burgstaller, et al.
Pageof 1